قالب وردپرس درنا توس
Home / Business / Bristol-Myers merger may depend on Wall Street's highest whisperers

Bristol-Myers merger may depend on Wall Street's highest whisperers



B ristol-Myers Squibb (BMY), racing to convince the shareholders to restore the planned acquisition of Celgene (CELG) to $ 74 billion, could get its plans sharpened by a major influential financial adviser.

ISS and Glass Lewis, two global firms that make recommendations to institutional investors, are not yet entering the potential merger. Together, they claim an approximately 97 percent share of the stock market consulting market, and their verdict on the deal can ruin the biggest pharmaceutical acquisition in history.

Unlock this article by subscribing to STAT Plus and enjoy the first 30 days for free!

GOT STARTED


Source link